Clinical trials: Drug Eluting Stent
Coronary Disease, Coronary Artery Disease
XIENCE V® Everolimus Eluting Coronary Stent System India Post-marketing Single-arm Study
XIENCE V® India is a prospective, open-label, multi-center, observational, single-arm study to evaluate XIENCE V® EECSS continued safety and effectiveness during commercial use in real world settings.
- Conditions
- Coronary Disease, Coronary Artery Disease, Coronary Restenosis
- Trial name
- XIENCE V India (NCT00631228)
- Testing
- XIENCE V® Everolimus Eluting Coronary Stent
- Where
- 18 sites in India
- Volunteers
- 1,000 people
- Sponsor
- Abbott Medical Devices
Arterial Occlusive Diseases
YUKON-drug-eluting Stent Below The Knee - Randomised Double-blind Study
The purpose of this study is to compare the effectiveness of the treatment with balloon-expandable YUKON-BTX-Sirolimus-eluting stent over the treatment with YUKON-BTX uncoated stent in patients with ischemic infrapopliteal…
- Trial name
- YUKON-BTK (NCT00664963)
- Testing
- Implantation of YUKON Sirolimus-eluting Stent, Implantation of YUKON Stent (uncoated)
- Where
- 3 sites in Germany
- Volunteers
- 130 people
- Sponsor
- Herz-Zentrums Bad Krozingen
Coronary Disease
BVS-OCT Imaging Study
The single center retrospective study evaluates the acute and long term outcomes of bioabsorbable drug-eluting scaffolds (BVS) implantation in 50 consecutive coronary artery disease (CAD) patients using optical coherence…
- Trial name
- NCT03194711
- Testing
- BVS implantation
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- Icahn School of Medicine at Mount Sinai
Coronary Angiography, Drug-eluting Stents
Proper Fractional Flow Reserve Criteria for Intermediate Lesions in the Era of Drug-eluting Stent
Angiographic evaluation for intermediate lesions is not always accurate. Fractional flow reserve-guided deferral strategy for these lesions showed the same event rate as routine intervention strategy.
- Conditions
- Coronary Angiography, Drug-eluting Stents, Fractional Flow Reserve, Myocardial
- Trial name
- DEFER-DES (NCT00592228)
- Testing
- Cypher, Taxus or Endeavor
- Where
- South Korea
- Volunteers
- 250 people
- Sponsor
- Seoul National University Hospital
Coronary Artery Disease
Efficacy and Safety of Xience in Coronary arEry Disease aLL-comers After stENTing Using the PRIME Platform (EXCELLENT-PRIME Registry)
Objectives: 1. To evaluate the safety and long-term effectiveness of coronary stenting with the XIENCE PRIMETM in a cohort of "real world" patients and lesion subsets. 2.
- Trial name
- NCT01605721
- Testing
- XIENCE PRIMETM everolimus-eluting coronary stent
- Where
- South Korea
- Volunteers
- 2,000 people
- Sponsor
- Seoul National University Hospital
Coronary Restenosis
Treatment of in-Stent Restenosis by Paclitaxel Coated PTCA Balloons (PACCOCATH - ISR II)
The PACCOCATH ISR II study is a randomized, double-blinded German multicenter trial on the efficacy and tolerance of a paclitaxel coated balloon catheter in coronary in-stent restenosis.
- Trial name
- NCT00409981
- Testing
- paclitaxel coated balloon catheter (device with drug)
- Where
- 5 sites in Germany
- Volunteers
- 56 people
- Sponsor
- University Hospital, Saarland
Peripheral Arterial Disease
Post-market Registry Study on the Safety and Efficacy of ZENFLEX Pro™ Peripheral Drug-eluting Stent System for Femoropopliteal Artery Lesions
This is a prospective, multi-center, single-arm post-market study evaluating the safety and effectiveness of the ZENFLEX Pro™ Drug-eluting Stent in treating femoropopliteal artery stenosis or occlusion.
- Trial name
- NCT07122167
- Testing
- Peripheral Drug-eluting Stent System
- Where
- Poland
- Volunteers
- 153 people
- Sponsor
- MDCECRO LLC
Coronary Disease, Coronary Artery Disease
ABSORB Clinical Investigation, Cohort B
The purpose of this study is to assess the safety and performance of the BVS Everolimus Eluting Coronary Stent System (EECSS) in the treatment of patients with a maximum of two de novo native coronary artery lesions located in…
- Conditions
- Coronary Disease, Coronary Artery Disease, Coronary Restenosis
- Trial name
- ABSORB B (NCT00856856)
- Testing
- Bioabsorbable Everolimus Eluting Coronary Stent
- Where
- 12 sites in Australia, Belgium and 6 more
- Volunteers
- 101 people
- Sponsor
- Abbott Medical Devices
Unstable Anginas, Non ST Segment Elevation Myocardial Infarction
OCT Evaluation of Early Vascular Repair in Patients With Non ST Elevation Acute Coronary Syndrome (NSTE-ACS)
This is a prospective study of a new generation of drug-eluting stent in the treatment of non ST elevation acute coronary syndrome (NSTE-ACS).
- Trial name
- EXPECT (NCT04375319)
- Testing
- OCT
- Where
- 2 sites in China
- Volunteers
- 60 people
- Sponsor
- Xuzhou Third People's Hospital
Diabetes Mellitus, Coronary Arterial Disease (CAD)
Randomised Trial of Dual Device Treatment Involving Drug-coated Balloon Angioplasty and Drug-eluting Stent Implantation Compared to Single Device Treatments in Patients With Diabetes Mellitus
Purpose of this study: The purpose of the study is to find out whether using a drug coated balloon in combination with a drug-eluting stent is better than the standard practice of using either device on its own.
- Conditions
- Diabetes Mellitus, Coronary Arterial Disease (CAD), de Novo Coronary Lesions, De Novo Stenosis
- Trial name
- DUBSTENT-DM (NCT07303439)
- Testing
- Percutaneous Coronary Intervention
- Where
- Ireland
- Volunteers
- 120 people
- Sponsor
- Royal College of Surgeons, Ireland
Coronary Disease
Drug-eluting-stents for Unprotected Left Main Stem Disease (ISAR-LEFT-MAIN)
The purpose of this study is to evaluate the efficacy of sirolimus- and paclitaxel-eluting stents for treatment of unprotected left main coronary artery disease.
- Trial name
- NCT00133237
- Testing
- Sirolimus-eluting stent, Paclitaxel-eluting stent
- Where
- 2 sites in Germany
- Volunteers
- 607 people
- Sponsor
- Deutsches Herzzentrum Muenchen
Coronary Artery Disease
IVUS-guided DES Implantation in Coronary Calcification
Coronary calcified lesion is associated with a poor clinical outcome. Intravascular ultrasound (IVUS) provides anatomic information in detail about reference vessel dimensions and lesion characteristics including severity of…
- Trial name
- ULTIMATE IV (NCT05800002)
- Testing
- Intravascular ultrasound, Angiography
- Where
- China
- Volunteers
- 864 people
- Sponsor
- Nanjing First Hospital, Nanjing Medical University
Coronary Artery Disease
(EASY)-IMProving Adherence to Clopidogrel Trial (IMPACT))
The purpose of this study is to test the impact of a multidisciplinary approach to improve the adhesion and persistence to Clopidogrel therapy.
- Trial name
- EASY-IMPACT (NCT01134679)
- Testing
- Multi-disciplinary disease management approach
- Where
- Canada
- Volunteers
- 300 people
- Sponsor
- Laval University
Chronic Rhinosinusitis (CRS)
Product Surveillance Registry; Ear, Nose and Throat - EXTEND Cohort
The purpose of this study is to confirm long-term clinical safety and performance, acceptability of identified risks, and detect emerging risks based on factual evidence for the PROPEL family of products when used according to…
- Trial name
- NCT06671561
- Testing
- Observational data collection from patients with chronic rhinosinusitis (CRS) receiving PROPEL sinus implant(s) following functional endoscopic sinus surgery (FESS)
- Sponsor
- Medtronic
Acute Coronary Syndromes, STEMI
Early Single Antiplatelet Therapy After IVUS-Guided PCI in Acute Coronary Syndrome
This is a prospective, open-label, multicenter, randomized, phase IV clinical trial designed to evaluate the safety and efficacy of early aspirin discontinuation followed by potent P2Y12 inhibitor monotherapy after intravascular…
- Conditions
- Acute Coronary Syndromes, STEMI, NSTEMI, Unstable Angina
- Trial name
- SAPT-ACS (NCT07684742)
- Testing
- Early P2Y12 Inhibitor Monotherapy, Standard Dual Antiplatelet Therapy
- Where
- South Korea
- Volunteers
- 1,900 people
- Sponsor
- Gyeongsang National University Hospital
Coronary Disease
Multi-Center Clinical Trial: Evaluation of Effectiveness and Safety
This trial aims to demonstrate the non-inferiority of the CI-CMS-005 Coronary Stent System to the study device as well as to the TAXUS™ Express2™ Drug-Eluting Coronary Stent System in in-segment late lumen loss at 9 months after…
- Trial name
- NCT00415961
- Testing
- CoStar Paclitaxel Drug-Eluting Coronary Stent System
- Where
- Japan
- Volunteers
- 120 people
- Sponsor
- Conor Medsystems
Coronary Artery Disease
The ENDEAVOR IV Clinical Trial: A Trial of a Coronary Stent System in Coronary Artery Lesions
The purpose of this study is to assess the equivalence in safety and efficacy of the Endeavor Drug Eluting Coronary Stent System when compared to the Taxus Paclitaxel-Eluting Coronary Stent System for the treatment of single de…
- Trial name
- ENDEAVOR IV (NCT00217269)
- Testing
- Coronary Artery Stenting
- Where
- United States
- Volunteers
- 1,548 people
- Sponsor
- Medtronic Vascular
Dyslipidemia, Coronary Heart Disease
Observational Study to Estimate the Rates of Outcomes in Patients Undergoing Percutaneous Coronary Intervention (PCI) With Drug Eluting Stent (DES) Implantation Who Take Statins
To estimate the rates of percutaneous coronary intervention (PCI) outcomes in patients after drug-eluting stents implantation who take statins.
- Trial name
- OPTIMA (NCT01047176)
- Where
- Russia
- Volunteers
- 602 people
- Sponsor
- AstraZeneca